SEC Tracker
Get the app
CVKD · XBRL financial data

Cadrenal Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (CVKD's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Aug 6, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cost of goods and services sold0*0*——————————
Research and development244361*6291,2547851,538*1,668—688666*772705
General and administrative898902*1,1261,2121,6752,740*2,255—2,0452,398*1,7422,635
Total operating expenses1,1431,264*1,7562,4672,4604,278*3,928—2,7343,065*2,5143,340
Operating income (loss)(1,143)(1,264)*(1,756)(2,467)(2,460)(4,278)*(3,928)—(2,734)(3,065)*(2,514)(3,340)
Interest expense0*0*——————————
Net income (loss)(1,036)(1,144)*(1,663)(2,393)(2,408)(4,187)*(3,845)—(2,686)(3,039)*(2,497)(3,323)
Earnings per share, basic USD per share(0.07)—(0.10)(0.15)(2.18)—(2.09)—(1.31)(1.43)*(1.04)(1.14)
Earnings per share, diluted USD per share(0.07)—(0.10)(0.15)(2.18)—(2.09)—(1.31)(1.43)*(1.04)(1.14)
Weighted average shares, basic thousands of shares15,39615,998*16,00816,0081,104—1,844—2,0442,122*2,4082,913
Weighted average shares, diluted thousands of shares15,39615,998*16,00816,0081,104—1,844—2,0442,122*2,4082,913

Balance sheet

CSV

Fiscal quarters (CVKD's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Aug 6, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents9,1098,4036,5665,0374,36410,0007,3365,0003,8604,0082,3082,388
Prepaid and other current assets—52———42576—116200428410
Total current assets9,2788,4927,0285,4444,67210,1137,945—4,0804,3192,8555,584
Property and equipment, net3221175—6553
Right-of-use asset27211592———————
Total assets9,3128,5197,0485,4574,67910,1247,953—4,0884,3272,8625,589
Accounts payable1421674007604971,5021,278—614651825872
Accrued liabilities3976384416977681,181562—739937240625
Total current liabilities5648278561,4651,2672,6841,840—1,3531,5881,0651,497
Lease liability, non-current2———————————
Total liabilities5668278561,4651,2672,6841,840—1,3531,5881,0651,497
Accumulated deficit(13,927)(15,071)(16,735)(19,128)(21,536)(25,723)(29,568)—(35,921)(38,960)(41,457)(44,779)
Total stockholders' equity8,7467,6926,1923,9923,4127,4406,113—2,7352,7391,7974,092
Total liabilities and equity9,3128,5197,0485,4574,67910,1247,953—4,0884,3272,8625,589
Common shares outstanding (cover page) thousands of shares13,02316,00816,00816,0081,6591,8801,9672,0472,0762,5072,8683,568

Cash flows

CSV

Fiscal quarters (CVKD's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Aug 6, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(1,036)(1,144)*(1,663)(2,393)(2,408)(4,187)*(3,845)—(2,686)(3,039)*(2,497)(3,323)
Stock-based compensation153*103*163193*300*763*549—473*325*252672*
Net cash from operating activities(628)*(694)*(1,836)(1,529)*(2,201)*(1,791)*(4,649)—(2,357)*(2,570)*(3,002)(2,233)*
Purchases of property and equipment0*0*———year only3—2*0*——
Net cash from investing activities(0)*0*———year only(3)—(2)*0*——
Proceeds from issuing common stock—————3,616*2,055—668*846*(64)1,522*
Net cash from financing activities6,507*(13)*00*1,528*7,451*1,970—648*2,718*1,3032,312*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Cadrenal Therapeutics2,388not reported(2,233)*3.6M1.1 quarters 10-QJun 30, 2026
Curis5,0730(9,646)*2.1M0.5 quarters 10-QJun 30, 2026
Kala Bio229not reported(1,535)*19.3M4.7 quarters 10-QJun 30, 2026
Lexaria Bioscience3,5000(1,635)*24.8M2.2 quarters 10-QMay 31, 2026
Pulmatrix2,168not reported(1,106)*3.7M2.0 quarters 10-QJun 30, 2026
Dyadic International1,425961(1,818)*36.4M1.7 quarters 10-QJun 30, 2026
Scynexis10,487235(14,885)*9.9M3.6 quarters 10-QJun 30, 2026
Palatin Technologies7,492301*(2,690)*1.8M2.8 quarters 10-KJun 30, 2026
Aytu Biopharma26,30816,106*4,406*10.9M— 10-KJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.